NASDAQ: SCTXScribe Therapeutics Inc Stock
$21.65
Updated Jul 24, 2026
SCTX Price
$21.65
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$21.00
52 Week High
$25.49
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.65
Operating Cash Flow
N/A
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCTX Overview
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCTX's potential to beat the market
- SCTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SCTX
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $253.87 | A | |
| $11.03 | A | |
| $8.32 | A |
Be the first to know about important SCTX news, forecast changes, insider trades & much more!
SCTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCTX's short-term liabilities ($79.72M) exceed its short-term assets ($52.40M)
Short-term Liabilities Financials
SCTX's short-term assets ($52.40M) exceed its long-term liabilities ($23.87M)
Long-term Liabilities Financials
SCTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more SCTX due diligence checks available for Premium users.
Valuation
SCTX's financial health
Profit margin
Revenue
$2.2M
Net Income
-$17.3M
Profit Margin
-776.8%
Assets to liabilities
Assets
$65.2M
Liabilities
$103.6M
Debt to equity
-0.65
SCTX's short-term liabilities ($79.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCTX's short-term assets ($52.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
$15.6M
Financing
-$411.0k
Scribe Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.